Salvinorin a and related compounds as therapeutic drugs for psychostimulant-related disorders - PubMed

Review

Salvinorin a and related compounds as therapeutic drugs for psychostimulant-related disorders

R G dos Santos et al. Curr Drug Abuse Rev. 2014.

Abstract

Pharmacological treatments are available for alcohol, nicotine, and opioid dependence, and several drugs for cannabis-related disorders are currently under investigation. On the other hand, psychostimulant abuse and dependence lacks pharmacological treatment. Mesolimbic dopaminergic neurons mediate the motivation to use drugs and drug-induced euphoria, and psychostimulants (cocaine, amphetamine, and methamphetamine) produce their effects in these neurons, which may be modulated by the opioid system. Salvinorin A is a κ-opioid receptor agonist extracted from Salvia divinorum, a hallucinogenic plant used in magico-ritual contexts by Mazateca Indians in México. Salvinorin A and its analogues have demonstrated anti-addiction effects in animal models using psychostimulants by attenuating dopamine release, sensitization, and other neurochemical and behavioral alterations associated with acute and prolonged administration of these drugs. The objective of the present article is to present an overview of the preclinical evidence suggesting anti-addictive effects of salvinorin A and its analogues.

Similar articles

• Salvinorin A analogs and other κ-opioid receptor compounds as treatments for cocaine abuse.

  Kivell BM, Ewald AW, Prisinzano TE. Kivell BM, et al. Adv Pharmacol. 2014;69:481-511. doi: 10.1016/B978-0-12-420118-7.00012-3. Adv Pharmacol. 2014. PMID: 24484985 Free PMC article. Review.

• Selective natural kappa opioid and cannabinoid receptor agonists with a potential role in the treatment of gastrointestinal dysfunction.

  Fichna J, Schicho R, Janecka A, Zjawiony JK, Storr M. Fichna J, et al. Drug News Perspect. 2009 Sep;22(7):383-92. doi: 10.1358/dnp.2009.22.7.1400219. Drug News Perspect. 2009. PMID: 19890495 Review.

• A unique natural selective kappa-opioid receptor agonist, salvinorin A, and its roles in human therapeutics.

  Cruz A, Domingos S, Gallardo E, Martinho A. Cruz A, et al. Phytochemistry. 2017 May;137:9-14. doi: 10.1016/j.phytochem.2017.02.001. Epub 2017 Feb 10. Phytochemistry. 2017. PMID: 28190678

• Pharmacology and anti-addiction effects of the novel κ opioid receptor agonist Mesyl Sal B, a potent and long-acting analogue of salvinorin A.

  Simonson B, Morani AS, Ewald AW, Walker L, Kumar N, Simpson D, Miller JH, Prisinzano TE, Kivell BM. Simonson B, et al. Br J Pharmacol. 2015 Jan;172(2):515-31. doi: 10.1111/bph.12692. Epub 2014 Jul 1. Br J Pharmacol. 2015. PMID: 24641310 Free PMC article.

• Kappa Opioid Receptor Agonist Mesyl Sal B Attenuates Behavioral Sensitization to Cocaine with Fewer Aversive Side-Effects than Salvinorin A in Rodents.

  Kivell BM, Paton KF, Kumar N, Morani AS, Culverhouse A, Shepherd A, Welsh SA, Biggerstaff A, Crowley RS, Prisinzano TE. Kivell BM, et al. Molecules. 2018 Oct 11;23(10):2602. doi: 10.3390/molecules23102602. Molecules. 2018. PMID: 30314288 Free PMC article.

Cited by

• Dynorphin/kappa opioid receptor system regulation on amygdaloid circuitry: Implications for neuropsychiatric disorders.

  Limoges A, Yarur HE, Tejeda HA. Limoges A, et al. Front Syst Neurosci. 2022 Oct 5;16:963691. doi: 10.3389/fnsys.2022.963691. eCollection 2022. Front Syst Neurosci. 2022. PMID: 36276608 Free PMC article. Review.

• Influence of psychostimulants and opioids on epigenetic modification of class III histone deacetylase (HDAC)-sirtuins in glial cells.

  Sivalingam K, Doke M, Khan MA, Samikkannu T. Sivalingam K, et al. Sci Rep. 2021 Oct 29;11(1):21335. doi: 10.1038/s41598-021-00836-z. Sci Rep. 2021. PMID: 34716387 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Bentham Science Publishers Ltd.
  • Ingenta plc

• Medical

  • MedlinePlus Health Information